Clinical characteristics at initial diagnosis
| Clinical characteristics at initial diagnosis . | . | % . |
|---|---|---|
| Sex | ||
| N (m.d.) | 141 (0) | |
| Male | 84 | 60 |
| Female | 57 | 40 |
| Age at diagnosis | ||
| N (m.d.) | 141 (0) | |
| Mean (SD) | 54.0 (23.8) | |
| Median (Q1; Q3) | 62.1 (40.9; 71.8) | |
| Min; max | 1.4; 87.2 | |
| N (m.d.) | 138 (3) | |
| MH subtype | ||
| Primary | 89 | 64 |
| Secondary | 49 | 36 |
| Previous hematological malignancy | ||
| N (m.d.) | 46 (3) | |
| Follicular lymphoma | 13 | 28 |
| ALL | 11 | 24 |
| Chronic lymphocytic leukemia | 5 | 11 |
| Myelodysplastic syndrome | 5 | 11 |
| Diffuse large B-cell lymphoma | 3 | 7 |
| Marginal zone lymphoma | 2 | 4 |
| Langerhans cell histiocytosis | 2 | 4 |
| B-cell lymphoma (not specified) | 1 | 2 |
| Multiple myeloma | 1 | 2 |
| Hairy cell leukemia | 1 | 2 |
| Anaplastic large cell lymphoma | 1 | 2 |
| Chronic myelomonocytic leukemia | 1 | 2 |
| Timeline of diagnosis | ||
| N (m.d.) | 39 (10) | |
| Prior | 31 | 79 |
| Concomitant | 8 | 21 |
| Hematological malignancy treatment | ||
| N (m.d.) | 34 (15) | |
| No | 6 | 18 |
| Yes | 28 | 82 |
| Disease extent at diagnosis | ||
| N (m.d.) | 135 (6) | |
| Localized | 44 | 33 |
| Disseminated | 91 | 67 |
| Histiocytosis affected organs | ||
| Lymph node, N (m.d.) | 133 (8) | |
| Yes | 81 | 61 |
| Bone, N (m.d.) | 127 (14) | |
| Yes | 37 | 29 |
| Liver, N (m.d.) | 126 (15) | |
| Yes | 25 | 20 |
| Skin, N (m.d.) | 130 (11) | |
| Yes | 25 | 19 |
| Lung, N (m.d.) | 128 (13) | |
| Yes | 21 | 16 |
| Spleen, N (m.d.) | 127 (14) | |
| Yes | 20 | 16 |
| Soft tissue, N (m.d.) | 129 (12) | |
| Yes | 20 | 16 |
| Digestive tract, N (m.d.) | 129 (12) | |
| Yes | 18 | 14 |
| Bone marrow, N (m.d.) | 127 (14) | |
| Yes | 15 | 12 |
| Central nervous system, N (m.d.) | 127 (14) | |
| Yes | 7 | 6 |
| Oral mucosa, N (m.d.) | 128 (13) | |
| Yes | 4 | 3 |
| Genito anal mucosa, N (m.d.) | 127 (14) | |
| Yes | 2 | 2 |
| Endometrium, N (m.d.) | 127 (14) | |
| Yes | 2 | 2 |
| Clinical characteristics at initial diagnosis . | . | % . |
|---|---|---|
| Sex | ||
| N (m.d.) | 141 (0) | |
| Male | 84 | 60 |
| Female | 57 | 40 |
| Age at diagnosis | ||
| N (m.d.) | 141 (0) | |
| Mean (SD) | 54.0 (23.8) | |
| Median (Q1; Q3) | 62.1 (40.9; 71.8) | |
| Min; max | 1.4; 87.2 | |
| N (m.d.) | 138 (3) | |
| MH subtype | ||
| Primary | 89 | 64 |
| Secondary | 49 | 36 |
| Previous hematological malignancy | ||
| N (m.d.) | 46 (3) | |
| Follicular lymphoma | 13 | 28 |
| ALL | 11 | 24 |
| Chronic lymphocytic leukemia | 5 | 11 |
| Myelodysplastic syndrome | 5 | 11 |
| Diffuse large B-cell lymphoma | 3 | 7 |
| Marginal zone lymphoma | 2 | 4 |
| Langerhans cell histiocytosis | 2 | 4 |
| B-cell lymphoma (not specified) | 1 | 2 |
| Multiple myeloma | 1 | 2 |
| Hairy cell leukemia | 1 | 2 |
| Anaplastic large cell lymphoma | 1 | 2 |
| Chronic myelomonocytic leukemia | 1 | 2 |
| Timeline of diagnosis | ||
| N (m.d.) | 39 (10) | |
| Prior | 31 | 79 |
| Concomitant | 8 | 21 |
| Hematological malignancy treatment | ||
| N (m.d.) | 34 (15) | |
| No | 6 | 18 |
| Yes | 28 | 82 |
| Disease extent at diagnosis | ||
| N (m.d.) | 135 (6) | |
| Localized | 44 | 33 |
| Disseminated | 91 | 67 |
| Histiocytosis affected organs | ||
| Lymph node, N (m.d.) | 133 (8) | |
| Yes | 81 | 61 |
| Bone, N (m.d.) | 127 (14) | |
| Yes | 37 | 29 |
| Liver, N (m.d.) | 126 (15) | |
| Yes | 25 | 20 |
| Skin, N (m.d.) | 130 (11) | |
| Yes | 25 | 19 |
| Lung, N (m.d.) | 128 (13) | |
| Yes | 21 | 16 |
| Spleen, N (m.d.) | 127 (14) | |
| Yes | 20 | 16 |
| Soft tissue, N (m.d.) | 129 (12) | |
| Yes | 20 | 16 |
| Digestive tract, N (m.d.) | 129 (12) | |
| Yes | 18 | 14 |
| Bone marrow, N (m.d.) | 127 (14) | |
| Yes | 15 | 12 |
| Central nervous system, N (m.d.) | 127 (14) | |
| Yes | 7 | 6 |
| Oral mucosa, N (m.d.) | 128 (13) | |
| Yes | 4 | 3 |
| Genito anal mucosa, N (m.d.) | 127 (14) | |
| Yes | 2 | 2 |
| Endometrium, N (m.d.) | 127 (14) | |
| Yes | 2 | 2 |
max, maximum; m.d., missing data; min, minimum; SD, standard deviation.